Form 4: AN2 Therapeutics CEO Eric Easom Buys 10,000 Shares, Signaling Confidence

AN2 Therapeutics, Inc. CEO Eric Easom has purchased 10,000 shares of common stock at an average price of $1.0665, increasing his direct beneficial ownership.

Summary

• Eric Easom, the Chief Executive Officer and a Director of AN2 Therapeutics, Inc. (ANTX), acquired 10,000 shares of the company's common stock.
• The transaction took place on June 2, 2025, at a weighted average purchase price of $1.0665 per share, with individual transaction prices ranging from $1.05 to $1.0699.
• Following this acquisition, Mr. Easom's direct beneficial ownership stands at 256,380 shares, which includes 145,250 restricted stock units (RSUs) set to vest annually over four years from January 1, 2025, and an additional 99,000 RSUs vesting annually over four years from January 1, 2024.
• Mr. Easom also holds significant indirect beneficial ownership, including 1,065,766 shares through the Easom Living Trust dated August 21, 2019, and 97,058 shares each through the C. Easom Irrevocable Trust and the Jude Easom Irrevocable Trust, both dated October 8, 2021.

Sentiment

Score: 8

Explanation: The purchase of shares by the CEO indicates strong insider confidence, which is a positive signal for investors. While the amount is not exceptionally large, it adds to the CEO's direct holdings and aligns interests.

Positives

• The purchase of 10,000 shares by CEO Eric Easom demonstrates strong insider confidence in AN2 Therapeutics, Inc.'s current valuation and future prospects.
• This acquisition increases the CEO's direct equity stake, further aligning management's financial interests with those of the company's shareholders.

Future Outlook

The document does not provide specific forward-looking statements or guidance beyond the vesting schedules of restricted stock units, which are tied to continuous service.

Industry Context

This insider purchase by the CEO of AN2 Therapeutics, a biotechnology company, is a common signal of management's belief in the company's future prospects, particularly in a sector often characterized by high R&D costs and long development cycles. Such purchases can be viewed positively by investors seeking signs of confidence from within the company, especially when the stock price may be low.

Related Party Transactions

• The document details indirect beneficial ownership through the Easom Living Trust, C. Easom Irrevocable Trust, and Jude Easom Irrevocable Trust, which are related party holdings.

Stakeholder Impact

• Shareholders may view the CEO's share purchase as a positive sign of confidence in the company's future, potentially increasing investor sentiment.
• Employees, particularly those with equity compensation, might see this as a reaffirmation of the company's stability and growth potential.

Key Dates

Recommendation

Keywords

AN2 Therapeutics, ANTX, Eric Easom, Insider Trading, Stock Purchase, Form 4, CEO, Biotechnology, Pharmaceuticals, Equity Acquisition